Statistically significant lower risk is seen for mortality, ventilation, hospitalization, recovery, and viral clearance. 4 studies from 2 independent teams in 2 countries show significant improvements.
Meta analysis using the most serious outcome reported shows 78% [70‑83%] lower risk. Results are similar for peer-reviewed studies. Currently all studies are RCTs.
Studies to date are from only 2 different groups.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective.
All data to reproduce this paper and sources are in the appendix. Zheng et al. present another meta analysis for proxalutamide, showing significant improvements for mortality, mechanical ventilation, hospitalization, and clinical improvement.
Covid Analysis et al., Sep 2024, preprint, 1 author.
